Brief Report

Intravascular hemolysis following low dose daily rifampin

Corresponding Author

Cindy E. Neunert MD

[email protected]

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063.===Search for more papers by this author

Geeta S. Paranjape MD,

Geeta S. Paranjape MD

Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

Scott Cameron MD, PhD,

Scott Cameron MD, PhD

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

Zora R. Rogers MD,

Zora R. Rogers MD

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

Cindy E. Neunert MD,

Corresponding Author

Cindy E. Neunert MD

[email protected]

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063.===Search for more papers by this author

Geeta S. Paranjape MD,

Geeta S. Paranjape MD

Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

Scott Cameron MD, PhD,

Scott Cameron MD, PhD

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

Zora R. Rogers MD,

Zora R. Rogers MD

Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Search for more papers by this author

First published: 09 October 2008

https://doi.org/10.1002/pbc.21709

Citations: 9

Share a link

Email
Wechat
Bluesky

Abstract

We report two pediatric patients with rifampin-induced hemolysis following treatment with low daily dose rifampin for methicillin-resistant Staphylococcus aureus (MRSA). With the increased use of rifampin to treat MRSA, physicians should be aware that patients receiving rifampin therapy are at risk for hemolysis, even at low daily doses. Pediatr Blood Cancer 2008;51:821–823. © 2008 Wiley-Liss, Inc.

REFERENCES

1 Ellis MW, Lewis JS, II. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005; 18: 496–501.
10.1097/01.qco.0000186850.54040.fc
CAS PubMed Web of Science® Google Scholar
2 Girling D. Adverse reactions to rifampin in antituberculosis regimens. J Antimicrob Chemother 1977; 3: 115–132.
10.1093/jac/3.2.115
CAS PubMed Web of Science® Google Scholar
3 De Vriese AS, Robbrecht DL, Vanholder RC, et al. Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998; 31: 108–115.
10.1053/ajkd.1998.v31.pm9428460
CAS PubMed Web of Science® Google Scholar
4 Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5: S440–S450.
10.1093/clinids/5.Supplement_3.S440
CAS PubMed Web of Science® Google Scholar
5 Poole G, Stradling P, Worlledge S. Potentially Serious side effects of high-dose twice-weekly rifampin. Br Med J 1971; 3: 343–347.
10.1136/bmj.3.5770.343
CAS PubMed Web of Science® Google Scholar
6 Oguz A, Kanra T, Gokalp A, et al. Acute hemolytic anemia caused by irregular rifampin therapy. Turkish J Pediatr 1989; 31: 83–88.
CAS Web of Science® Google Scholar
7 Gupta A, Sakhuja V, Gupta KL, et al. Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Int J Lepr Other Mycobact Dis 1992; 60: 185–188.
CAS PubMed Web of Science® Google Scholar
8 Brecher M. Technical manual. Bethesda, MD: AABB American Association of Blood Banks; 2005.
Google Scholar
9 Petz LDGG. Immune hemolytic anemias. Philadelphia: Churchill Livingstone; 2004.
Google Scholar
10 Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired meticillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5: 275–286.
10.1016/S1473-3099(05)70112-2
PubMed Web of Science® Google Scholar
11 Schubothe H, Weber S. Rifampin-dependent reactions against erythrocytes in sera of patients receiving rifampin therapy. Scand J Respir Dis 1973; S84: 53–59.
Google Scholar
12 Chan WC, O'Mahoney MG, Yu DY, et al. Renal failure during intermittent rifampicin therapy. Tubercle 1975; 56: 191–198.
10.1016/0041-3879(75)90051-3
CAS PubMed Web of Science® Google Scholar
13 Duran-Suarez J, Martin-Vega C, Arglaques E, et al. Red cell I antigen as immune complex receptor in drug-induced hemolytic anemias. Vox Sang 1981; 41: 313–315.
10.1111/j.1423-0410.1981.tb01055.x
CAS PubMed Web of Science® Google Scholar
14 Pereira A, Sanz C, Cervantes F, et al. Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity. Ann Hematol 1991; 63: 56–58.
10.1007/BF01714964
CAS PubMed Web of Science® Google Scholar
15 Covic A, Golea O, Segall L, et al. A Clinical description of rifampin- induced acute renal failure in 170 consecutive cases. J Indian Med Assoc 2004; 102: 20–25.
CAS PubMed Google Scholar
16 Worlledge S. The detection of rifampin-dependent antibodies. Scand J Respir Dis 1973; 84s: 60–63.
Google Scholar
17 Seufert C. Acute renal failure after rifampin therapy. Scand J Respir Dis 1973; 84s: 174–179.
Google Scholar

Citing Literature

Volume51, Issue6

December 2008

Pages 821-823

Intravascular hemolysis following low dose daily rifampin

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Intravascular hemolysis following low dose daily rifampin

Abstract

REFERENCES

Citing Literature

References

Related

Information